0B68 Jimenez, Sergio A - Thomas Jefferson University - Thomas Jefferson University

Sergio A. Jimenez, MD

Contact Dr. Jimenez

233 South Tenth Street
Bluemle Life Sciences Building, Suite 509
Philadelphia, PA 19107

(215) 503-5042
(215) 923-4649 fax

Most Recent Peer-reviewed Publications

  1. Altered MCM protein levels and autophagic flux in aged and systemic sclerosis dermal fibroblasts
  2. Induction of a type I interferon signature in normal human monocytes by gadolinium-based contrast agents: Comparison of linear and macrocyclic agents
  3. Role of Cellular Senescence and NOX4-Mediated Oxidative Stress in Systemic Sclerosis Pathogenesis
  4. Collagen content in skin and internal organs of the Tight Skin mouse: An animal model of scleroderma
  5. 2013 classification criteria for systemic sclerosis: An American college of rheumatology/European league against rheumatism collaborative initiative
  6. Acute retinal artery occlusion in systemic sclerosis: A rare manifestation of systemic sclerosis fibroproliferative vasculopathy
  7. Potential role of human-specific genes, human-specific microRNAs and human-specific non-coding regulatory RNAs in the pathogenesis of Systemic Sclerosis and Sjögren's Syndrome
  8. Strategies for anti-fibrotic therapies
  9. Caveolin-1 deficiency induces spontaneous endothelial-to-mesenchymal transition in murine pulmonary endothelial cells in vitro
  10. Predictors of early mortality in systemic sclerosis: A case-control study comparing early versus late mortality in systemic sclerosis
  11. Effects of scleroderma antibodies and pooled human immunoglobulin on anal sphincter and colonic smooth muscle function
  12. Chitinase 1 is a biomarker for and therapeutic target in scleroderma-associated interstitial lung disease that augments TGF-β1 signaling
  13. Systemic sclerosis disease modification clinical trials design: Quo vadis?
  14. Gadolinium compounds signaling through TLR 4 and TLR 7 in normal human macrophages: Establishment of a proinflammatory phenotype and implications for the pathogenesis of nephrogenic systemic fibrosis
  15. Molecular mechanisms of endothelial to mesenchymal cell transition (EndoMT) in experimentally induced fibrotic diseases
  16. A prospective observational study of mycophenolate mofetil treatment in progressive diffuse cutaneous systemic sclerosis of recent onset
  17. Effect of oxidative stress on protein tyrosine phosphatase 1B in scleroderma dermal fibroblasts
  18. Items for developing revised classification criteria in systemic sclerosis: Results of a consensus exercise
  19. Effect of protein kinase C delta (PKC-δ) inhibition on the transcriptome of normal and systemic sclerosis human dermal fibroblasts in vitro
  20. Tyrosine kinase inhibitor therapy for systemic sclerosis: Quo Vadis?